| Type 2 Diabetes Mellitus |
1 |
1 |
| Atrial Fibrillation |
0 |
0.98 |
| SGLT2 Inhibitor |
0 |
0.99 |
| Heart |
0 |
0.42 |
| Heart Failure (HF) |
0 |
0.42 |
| Coronary Artery Disease (CAD) |
0 |
0.41 |
| Acute Heart Failure (HF) |
0 |
0.34 |
| GLP-1 Receptor Agonist |
0 |
0.33 |
| Cardiovascular Risk Management |
0 |
0.28 |
| Hypertension |
0 |
0.27 |
| Arrhythmia |
0 |
0.23 |
| Match |
0 |
0.19 |
| Receptors |
0 |
0.19 |
| Medical Life |
0 |
0.13 |
| Hospital |
0 |
0.12 |
| Medicare |
0 |
0.12 |
| Cardiovascular disease |
0 |
0.08 |
| Oxidative Stress |
0 |
0.08 |
| Stress |
0 |
0.08 |
| Renal Disease |
0 |
0.05 |
| Atrial Flutter |
0 |
0.04 |
| Blood |
0 |
0.04 |
| California |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Diuretics |
0 |
0.04 |
| Dorsum |
0 |
0.04 |
| Drug Costs |
0 |
0.04 |
| Generics |
0 |
0.04 |
| Geriatrics |
0 |
0.04 |
| Kidney |
0 |
0.04 |
| Meta-Analysis |
0 |
0.04 |
| Pharmacoeconomics |
0 |
0.04 |
| Pharmacoepidemiology |
0 |
0.04 |
| Healthcare and Medical Technology |
0 |
0.03 |